drugset
drugset / Trial / NCT04982432

Orismilast for the Treatment of Mild to Severe Hidradenitis Suppurativa

NCT04982432 ↗

Phase 2 Unknown 24 enrolled Gregor Jemec UNION therapeutics · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the efficacy and safety of oral administration of orismilast for treatment of mild, moderate, or severe hidradenitis suppurativa (HS) in adults.

Timeline

Start
2021-10-01
Primary completion
2022-12-01
Completion
2022-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject LEO 32731 Unknown 40 mg Oral

Indications

hidradenitis suppurativa